Actively Recruiting
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
Led by The First Affiliated Hospital of Soochow University · Updated on 2025-09-08
27
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
ETP-ALL like patients have poor outcomes and prognosis, and the optimal therapeutic approaches are poorly characterized. The goal of this clinical trial is to evaluate the efficacy and safety of the venetoclax combined with azacitidine, chidamide, vindesine, and dexamethasone regimen in newly diagnosed ETP-ALL like patinets (including ETP-ALL, near ETP-ALL and T-ALL with myeloid mutations) .
CONDITIONS
Official Title
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 14 and 65 years inclusive
- Diagnosed with ETP-ALL like disease meeting specific flow cytometry criteria for ETP-ALL, near-ETP-ALL, or T-ALL with myeloid mutations
- Newly diagnosed patients with no prior induction therapy except limited allowed treatments
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
- Expected survival of more than 6 months
- Able to understand the study and willing to provide informed consent
You will not qualify if you...
- Pregnancy, breastfeeding, or unwillingness to use contraception in women of childbearing potential
- Uncontrolled active infection including bacterial, fungal, or viral infections; active HBV, HCV, or HIV infection
- Severe organ dysfunction including cardiac insufficiency (LVEF ≤40%, heart failure, unstable coronary artery disease, severe arrhythmia), respiratory failure (PaO2 ≤60 mmHg), liver impairment (total bilirubin ≥2x ULN or ALT/AST ≥3x ULN), renal impairment (serum creatinine ≥2 mg/dL or creatinine clearance ≤30 mL/min/1.73m2)
- History of hypersensitivity to any study drug or similar compounds
- Presence of central nervous system leukemia
- Any other condition making participation unsuitable as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215000
Actively Recruiting
Research Team
Y
Yang Xu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here